Last reviewed · How we verify
Zanidip
At a glance
| Generic name | Zanidip |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Target | Voltage-gated L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Hypertensive disorder
Common side effects
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- The Role of Skin Sodium Accumulation in Chronic Kidney Disease (NA)
- Bariatric Surgery and Pharmacokinetics of Lercanidipine
- Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) (PHASE4)
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment (PHASE4)
- Antihypertensive Efficacy of Fixed Combination Drug (PHASE4)
- Zainidip in Renal Artery Stenosis (PHASE4)
- Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zanidip CI brief — competitive landscape report
- Zanidip updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI